American Eagle Energy Announces Amendment to Senior Credit Facility With Morgan Stanley
01 Ottobre 2013 - 10:31PM
Marketwired
DENVER, CO--(Marketwired - October 01, 2013) - American Eagle Energy
Corporation (OTCQX: AMZG) announced that it has amended
its Senior Credit Facility with Morgan Stanley Capital Group Inc.
to reduce its working capital requirement from $33.0 million to
$23.5 million as a condition precedent to obtaining an additional
$40 million earmarked for the purpose of purchasing additional
interests in the Spyglass Project area in the Williston Basin in
northwestern Divide County, North Dakota from a joint partner.
ABOUT AMERICAN EAGLE ENERGY
CORPORATION
American Eagle Energy Corporation is an independent exploration
and production operator that is focused on acquiring acreage and
developing wells in the Williston Basin of North Dakota, targeting
the Bakken and Three Forks shale oil formations. The Company is
based in Denver, CO. More information about American Eagle can be
found at www.americaneagleenergy.com or by contacting investor
relations at 303-798-5235 or ir@amzgcorp.com. Company filings with
the Securities and Exchange Commission can be obtained free of
charge at the SEC's internet site at www.sec.gov.
SAFE HARBOR
This press release may contain forward-looking statements
regarding future events, including the purchase of additional
interests in the Spyglass Project, that are subject to the safe
harbors created under the Securities Act of 1933 (the "Securities
Act") and the Securities Exchange Act of 1934 (the "Exchange
Act"). All statements other than statements of historical
facts included in this press release regarding the Company's
financial position, business strategy, plans and objectives of
management for future operations, industry conditions, and
indebtedness covenant compliance are forward-looking
statements. When used in this report, forward-looking
statements are generally accompanied by terms or phrases such as
"estimate," "project," "predict," "believe," "expect,"
"anticipate," "possible," "target," "plan," "intend," "seek,"
"goal," "will," "should," "may" or other words and similar
expressions that convey the uncertainty of future events or
outcomes. Items contemplating or making assumptions about,
actual or potential future sales, market size, collaborations, and
trends or operating results also constitute such forward-looking
statements.
Forward-looking statements involve inherent risks and
uncertainties and important factors (many of which are beyond the
Company's control) that could cause actual results to differ
materially from those set forth in the forward-looking statements,
including the following: general economic or industry
conditions, nationally and/or in the communities in which the
Company conducts business, changes in the interest rate
environment, legislation or regulatory requirements, conditions of
the securities markets, our ability to raise capital, changes in
accounting principles, policies, or guidelines, financial or
political instability, acts of war or terrorism, other economic,
competitive, governmental, regulatory and technical factors
affecting the Company's operations, products, services, and
prices.
The Company has based these forward-looking statements on its
current expectations and assumptions about future
events. While management considers these expectations and
assumptions to be reasonable, they are inherently subject to
significant business, economic, competitive, regulatory, and other
risks, contingencies, and uncertainties, most of which are
difficult to predict and many of which are beyond the Company's
control. The Company does not assume any obligations to update any
of these forward-looking statements.
INVESTOR RELATIONS CONTACT: Marty Beskow Vice President of
Capital Markets and Strategy American Eagle Energy Corporation
303-798-5235 ir@amzgcorp.com www.americaneagleenergy.comBrad Holmes
EnergyIR 713-654-4009 B_holmes@att.net
Grafico Azioni Immage Biotherapeutics (CE) (USOTC:IMMG)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Immage Biotherapeutics (CE) (USOTC:IMMG)
Storico
Da Giu 2023 a Giu 2024